Financial Performance - The company's operating revenue for Q1 2023 was CNY 75,710,434.22, representing an increase of 28.77% compared to the same period last year[5] - The net profit attributable to shareholders for Q1 2023 was CNY 6,686,853.20, a significant increase of 387.32% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 6,225,735.69, reflecting a remarkable increase of 558.28% compared to the previous year[5] - The basic earnings per share for Q1 2023 was CNY 0.0177, up by 378.38% year-on-year[5] - The total revenue for Q1 2023 was ¥75,710,434.22, representing an increase of 28.7% compared to ¥58,796,482.88 in Q1 2022[18] - The net profit for Q1 2023 was ¥6,686,853.20, a significant increase from ¥1,378,890.58 in Q1 2022, marking a growth of 385.5%[19] - The basic earnings per share of ¥0.0177 for Q1 2023, compared to ¥0.0037 in Q1 2022, representing a growth of 378.4%[19] Assets and Liabilities - The total assets at the end of Q1 2023 were CNY 1,005,621,806.46, a slight increase of 0.43% from the end of the previous year[6] - The total assets as of March 31, 2023, amounted to ¥1,005,621,806.46, slightly up from ¥1,001,329,612.78 as of December 31, 2022[15] - The total liabilities decreased to ¥328,960,581.90 from ¥334,306,129.32, indicating a reduction of approximately 1.0%[16] - The equity attributable to shareholders increased to CNY 676,661,224.56, marking a growth of 1.44% compared to the end of the previous year[6] Cash Flow - The company reported a net cash flow from operating activities of CNY -11,349,578.00, indicating a decrease of 10.51% year-on-year[5] - In Q1 2023, the cash inflow from operating activities was CNY 66,346,463.62, an increase of 12.5% compared to CNY 59,101,524.63 in Q1 2022[21] - The net cash flow from operating activities was -CNY 11,349,578.00, showing an improvement from -CNY 12,682,485.50 in the same period last year[21] - The total cash and cash equivalents at the end of Q1 2023 were CNY 70,793,279.18, compared to CNY 49,289,567.66 at the end of Q1 2022, reflecting a year-over-year increase of 43.7%[22] - The company reported a total cash outflow from operating activities of CNY 77,696,041.62, up from CNY 71,784,010.13 in Q1 2022, indicating a 8.5% increase[21] Research and Development - Research and development expenses increased by 41.02% year-on-year, primarily due to increased investment in pharmaceutical research[9] - Research and development expenses for Q1 2023 were ¥6,139,950.63, up from ¥4,354,071.54 in Q1 2022, an increase of 40.9%[18] Investment Income - The company experienced a 170.93% increase in investment income, attributed to profits from its associate company[9] - The company received CNY 192,022.02 in investment income, up from CNY 97,648.93 in Q1 2022, marking a 96.5% increase[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,280[10]

1、根据申请人《二次反馈意见回复》,2020年根据中国国际贸易仲裁委员 会于 2020 年 4 月 13 日就发行人与张孝清关于《盈利预测补偿协议》仲裁出具 的《裁决书》(〔2020〕中国贸仲京裁字第 0496 号)之裁定结果,申请人对 2018 年财务数据进行会计差错更正,确认业绩补偿金额调整了 2018年营业外收入增 加 13,257.32 万元。2020年申请人一次性大规模终止 79 项合同,导致当年冲减 收入 11,463.58 万元,并补转成本 1,689.64 万元。华威医药相当一部分在研项目 未预期完成且这些项目开始时间久远(有的甚至超过10年),截止 2021年底上 述合同资产余额 15,317.85 万元,已计提坏账准备 2,922.64 万元。礼华生物存在 同样的问题。 请申请人:(1)说明将上述事项确定为会计差错并进行追溯调整是否符合 会计准则的相关规定;(2)说明 2020 年一次性大规模终止合同导致当年大额收 入冲减的原因,相关情况在之前年度是否已经存在,上述合同对应的存货于 2019 年底是否存在重大减值迹象;(3)结合期后结算情况,说明相关合同资产减值 准备计提的合理性和充分性; ...

请发行人说明:(1) 公司一致性评价业务 2019年采用完工百分比法确认收入 的原因,与采用形象进度法确认收入的差异、对经营业绩的具体影响;(2)公司 各项业务设置不同收入确认时点和确认比例的原因及合理性,与行业可比公司是 否一致,各时点收入比例确认的依据,按行业通行的确认时点和确认比例模拟测 算公司收入、成本及利润情况,是否存在显著差异;(3)2020年后,相关节点收 入确认比例显著提高的原因、依据及合理性,是否符合业务开展实际,对经营业 绩的具体影响,是否存在通过变更会计政策调节业绩的情况。 希格玛会计师事务所(特殊普通合伙) Xigema Cpas(Special General Partnership) 关于新疆百花村医药集团股份有限公司向特定对象发行股票 申请文件的审核问询顾回复 上海证券交易所: 贵所于 2023年3月23日出具的上证上审(再融资)(2023)146号《关于新 疆百花村医药集团股份有限公司向特定对象发行股票申请文件的审核问询函》(以 下简称"问询函")已收悉。根据贵所问询函提出的要求,我们在审慎核查的基础 上,就问询函中的有关问题回复说明如下: 1、根据申报材料,发行人主要以形象进 ...

希格玛会计师事务所(特殊普通合伙) Xigema Cpas(Special General Partnership) 关于新疆百花村医药集团股份有限公司 非公开发行股票项目反馈意见的回复 中国证券监督管理委员会: 根据贵会 2022年3月7日下发的《中国证监会行政许可项目审查一次反馈意 见通知书》(220241 号)(以下简称"《反馈意见》")的要求,我们在审慎调查的基 础上,就《反馈意见》的相关问题作出如下答复: 反馈意见 9: 申请人于 2016 年完成资产置出并置入华威医药 CRO 业务资产, CRO 业务收入为申请人报告期内最主要的收入来源。最近三年一期,申请人扣非归 母净利润分别-68,622.79 万元、731.11 万元、 -36,923.75 万元、595.78 万元, 其中 2020 年营业收入 8,453.04 万元。公司股票于 2021 年 4 月 1 日起被实施 "退市风险警示"。请申请人:(1)说明报告期内业绩大幅波动的主要原因,业绩 大亏与微利交替出现的原因及合理性,是否与同行业公司一致,是否存在操纵公 司业绩规避退市等情况;(2)结合上述情况说明申请人持续经营是否存在重大风 险, ...

希格玛会计师事务所(特殊普通合伙) Xigema Cpas(Special General Partnership) 关于新疆百花村医药集团股份有限公司 非公开发行股票申请之二次反馈意见回复 中国证券监督管理委员会: 贵会 2022 年 6 月 24 日下发的《中国证监会行政许可项目审查二次反馈意 见通知书》(220241 号)(以下简称"《二次反馈意见》")收悉。根据贵会《二次 反馈意见》提出的要求,我们在审慎核查的基础上,就《二次反馈意见》中的有 关问题回复说明如下: 反馈意见 1:2018年至2021年,申请人实现的净利润分别为:亏损67,529.15 万元,盈利 3,438.47 万元、亏损 31,976.55 万元及盈利 5,987. 43 万元;过往 4 年申请人收入存在巨幅波动,2020年营业收入为8,453.04万元,远小于当期结 转的营业成本 22,143.09万元。截止 2021年12月31日,发行申请人存货余额 19,404.78 万元,主要为在研项目《占比 99.67%);合同资产余额 14,554. 33 万 元,全部为研发项目。 请申请人:(1)说明过往 4年经营业绩大幅波动的原因 ...

Financial Performance - The company achieved operating revenue of CNY 349.88 million in 2022, a year-on-year increase of 24.36% driven by new orders and accelerated project progress[19]. - New signed orders amounted to CNY 516 million, representing a growth rate of 39.84%, with pharmaceutical R&D orders at CNY 268 million, up 21.27%, and clinical service orders at CNY 248 million, up 67.57%[19]. - The net profit attributable to shareholders was CNY -34.75 million, a decrease of 158.09% compared to the previous year[19]. - The basic earnings per share for 2022 was CNY -0.0925, a decline of 157.99% from CNY 0.1595 in 2021[20]. - The total revenue for 2022 was 350 million yuan, representing a 24.36% increase from 281 million yuan in the previous year[32]. - The main business revenue for 2022 was CNY 346.37 million, up 24.54% from the previous year[58]. - The company reported a basic earnings per share and diluted earnings per share significantly lower than the previous year, reflecting the same factors affecting net profit[22]. Assets and Liabilities - The company's total assets at the end of 2022 were CNY 1.00 billion, an increase of 1.94% from CNY 982.31 million at the end of 2021[19]. - As of December 31, 2022, the total assets amounted to 1.001 billion yuan, with net assets of 667 million yuan[32]. - The company's net assets attributable to shareholders decreased by 2.10% to CNY 667.02 million from CNY 681.30 million in 2021[19]. - The total liabilities rose to CNY 334,306,129.32 in 2022 from CNY 296,060,953.02 in 2021, marking an increase of approximately 12.9%[200]. - The total equity attributable to shareholders decreased to CNY 667,023,483.46 in 2022 from CNY 681,303,920.51 in 2021, a decline of approximately 2.1%[200]. Cash Flow - The net cash flow from operating activities was CNY 53.18 million, reflecting a 53.15% increase compared to CNY 34.72 million in 2021[19]. - The operating cash flow net amount increased by 53.15% to CNY 53.18 million, driven by higher cash receipts from pharmaceutical research projects[54]. - The company's cash and cash equivalents increased by 56.22% to CNY 135,730.65 million compared to the previous period[78]. - The accounts receivable increased by 8.97% to CNY 19,352.18 million, primarily due to increased receivables from pharmaceutical R&D[78]. Research and Development - The company increased its R&D investment, leading to a rise in R&D expenses by 22.2312 million yuan[32]. - Research and development expenses surged by 423.36% to CNY 27.48 million, reflecting increased investment in pharmaceutical research[54]. - The company completed over 500 drug development applications, serving more than 50 of the top 100 pharmaceutical companies in China[31]. - The company has established five major technology platforms for drug formulation, enhancing its competitive edge in the market[50]. Market and Business Strategy - The CRO industry in China is projected to grow at a compound annual growth rate of approximately 26.5%, reaching a market size of 22.2 billion USD by 2024[39]. - The company is focusing on expanding its market presence through strategic partnerships and enhancing its service offerings in drug development and clinical trials[40]. - The company plans to enhance its integrated service capabilities through mergers and acquisitions or by building new businesses to meet the rising demand for one-stop services in the CRO industry[87]. - The company aims to become a leading domestic CRO/CDMO enterprise in the "pharmaceutical health" industry, focusing on enhancing core competencies through strategic cooperation and acquisitions[89]. Governance and Compliance - The company has conducted 9 board meetings and reviewed 47 proposals, ensuring compliance with governance standards and enhancing decision-making processes[99]. - The company has maintained a strong governance structure with experienced professionals in key management positions, ensuring effective oversight and strategic direction[110]. - The audit report confirmed that the financial statements fairly reflect the company's financial position as of December 31, 2022[187]. - The company has not reported any dissenting opinions from the board members regarding company matters during the year[115]. Social Responsibility and Environmental Initiatives - The company has committed to fulfilling its social responsibilities by strengthening safety management and environmental protection measures[38]. - The company invested 2.588 million CNY in environmental protection initiatives during the reporting period[138]. - The company implemented carbon reduction measures, successfully reducing CO2 equivalent emissions by 100 tons during the reporting period[141]. - The company actively participated in social welfare activities, including donations and fee reductions for merchants, and was involved in 5 national major science and technology projects[144].

Financial Performance - The company's operating revenue for the third quarter was ¥92,595,170.97, representing a year-on-year increase of 43.37%[3] - The net profit attributable to shareholders decreased by 85.82% to ¥701,253.11 compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 97.78% to ¥103,495.14[3] - Basic earnings per share for the third quarter were ¥0.0019, down 85.61% year-on-year[3] - Net profit for the first three quarters of 2022 was ¥10,995,714.37, compared to ¥54,931,343.97 in the same period of 2021, indicating a significant decline[19] - The company reported a basic earnings per share of ¥0.0293 for the first three quarters of 2022, down from ¥0.1463 in the same period of 2021[19] Cash Flow - Cash flow from operating activities increased by 43.63% to ¥11,098,789.78 in the third quarter[3] - The net cash flow from operating activities for the first three quarters of 2022 was ¥20,888,519.77, compared to a negative cash flow of ¥7,698,340.41 in the same period of 2021, indicating a significant improvement[21] - Total cash inflow from operating activities increased to ¥220,602,824.18 in 2022, up from ¥167,389,140.62 in 2021, reflecting a growth of approximately 31.8%[21] - Cash and cash equivalents at the end of the third quarter of 2022 stood at ¥54,839,041.53, up from ¥27,503,292.51 at the end of the same period in 2021, representing a year-over-year increase of approximately 99.5%[22] - The company’s cash flow from operating activities was positively impacted by a tax refund of ¥4,615,176.15 received in 2022, which was not recorded in 2021[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,012,265,016.76, an increase of 3.05% from the end of the previous year[4] - Total liabilities as of September 30, 2022, were ¥307,920,870.93, an increase from ¥296,060,953.02 at the end of 2021[16] - The company's equity attributable to shareholders increased by 3.38% to ¥704,344,145.83 compared to the end of the previous year[4] - The company's equity attributable to shareholders was ¥704,344,145.83 as of September 30, 2022, compared to ¥681,303,920.51 at the end of 2021[16] Expenses - The significant decrease in net profit was primarily due to increased R&D and equity incentive expenses[6] - Sales expenses rose by 107.37% mainly due to the expansion of sales teams at Huawai Medicine and Lihua Biotech[7] - Operating expenses surged by 909.93% mainly due to salary payments for personnel in epidemic-affected areas[7] - Research and development expenses increased to ¥17,282,320.53 in the first three quarters of 2022, up from ¥3,253,778.41 in 2021, reflecting a focus on innovation[18] Investments - Trading financial assets increased by 100% due to the purchase of bank financial products during the period[7] - Investment income plummeted by 190.66% due to increased losses from investments in the associated company Kangyuan Huawai[7] - The company experienced an investment loss of ¥2,283,072.68 in the first three quarters of 2022, compared to a loss of ¥785,486.46 in 2021[18] Shareholder Information - The total number of ordinary shareholders increased from 14,149 to 20,345 during the reporting period[11] - The company acquired a 49% stake in Nanjing Baihua Xinxing Biopharmaceutical Technology Co., Ltd. for 4.9 million RMB, making it a wholly-owned subsidiary[11] - The total share capital increased from 375,134,355 shares to 376,403,355 shares due to stock option exercises[11] Other Income - Other income decreased by 96.77% primarily due to significant debt restructuring gains in the previous year[7]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately CNY 163.76 million, representing a 36.70% increase compared to the same period last year[15]. - Net profit attributable to shareholders decreased by 79.39% to approximately CNY 10.29 million, primarily due to a one-time gain from debt restructuring in the previous year[15][16]. - The basic earnings per share dropped by 79.43% to CNY 0.0274, while the diluted earnings per share decreased by 79.65% to CNY 0.0271[15]. - The net profit after deducting non-recurring gains increased by 665.13% to approximately CNY 9.92 million, indicating improved operational efficiency[15][16]. - The company reported a significant increase in sales expenses, which rose by 108.98% to ¥5,321,348.11, attributed to the expansion of sales teams[47]. - The comprehensive income for the first half of 2022 was CNY 5,778,801.61, compared to CNY 48,525,478.98 in the same period of 2021, indicating a significant decrease of approximately 88.14%[123][124]. Cash Flow and Assets - The net cash flow from operating activities improved significantly to approximately CNY 9.79 million, compared to a negative cash flow of CNY 15.43 million in the previous year[15][16]. - The company's total assets at the end of the reporting period were approximately CNY 985.20 million, a slight increase of 0.29% from the end of the previous year[15]. - Cash and cash equivalents at the end of the first half of 2022 stood at ¥53,266,463.74, up from ¥27,840,234.56 at the end of the first half of 2021[116]. - The company's cash and cash equivalents at the end of the reporting period amounted to ¥53,266,463.74, down from ¥86,884,849.85 at the beginning of the period[99]. - The total current assets increased to ¥484,750,328.68 from ¥468,093,854.92, indicating a growth of about 3.5%[99]. Research and Development - R&D expenses increased by 377.97% to 10.48 million yuan, reflecting the company's commitment to enhancing its technical service capabilities[42]. - The company has invested in advanced research facilities, including over 450 high-performance liquid chromatography instruments, enabling simultaneous execution of multiple research projects[31]. - The company is investing heavily in R&D, with a budget allocation of 200 million yuan for the development of new drugs and technologies in 2022[78]. - The company has a research and development team of 533 professionals, with 77% holding advanced degrees, ensuring high-quality service delivery[31]. Market and Growth Outlook - The CRO industry in China is projected to grow at a compound annual growth rate (CAGR) of 26.5%, reaching a market size of $22.2 billion by 2024[21]. - The clinical research phase of the CRO market is expected to grow at a CAGR of 30.0%, reaching $13.7 billion by 2024[21]. - The company provided a positive outlook for the second half of 2022, projecting a revenue growth of 25% driven by new product launches and market expansion efforts[75]. - The company aims to expand its business scope in the CRO industry to achieve vertical integration and meet comprehensive outsourcing needs[23]. Strategic Initiatives - The company signed new orders worth CNY 213.81 million during the reporting period, a growth rate of 39.07%, with clinical services orders increasing by 77.22%[16]. - The company has established a risk-sharing model with pharmaceutical companies to enhance revenue through profit-sharing post-drug launch[22]. - The company is considering strategic acquisitions to enhance its market position, with potential targets identified in the pharmaceutical sector[78]. - A strategic acquisition of a local pharmaceutical company is in progress, expected to enhance the company's product portfolio and distribution network[76]. Compliance and Governance - The management emphasized the importance of compliance and ethical practices in all business operations to safeguard shareholder interests[76]. - The company has committed to not engage in any business activities that compete with its listed operations, ensuring no conflicts of interest[74]. - The company will adhere to market rules and principles of fairness in any necessary related transactions[74]. Risks and Challenges - The company faces market competition risks due to the evolving pharmaceutical industry landscape, which may pressure costs and revenue growth[57]. - Regulatory changes in the pharmaceutical R&D and manufacturing sectors pose significant risks to the company's future stability and growth[58]. - Long-cycle contract execution risks exist due to the complexity of pharmaceutical R&D, which may lead to deviations in project timelines and expected revenues[59]. - The company is at risk of losing core technical talent due to increasing competition for skilled professionals in the pharmaceutical R&D sector[60].

新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 公告编号：2022-045 新疆百花村医药集团股份有限公司关于参加 2022 年新疆辖区 投资者网上集体接待日暨上市公司业绩说明会活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 为便于广大投资者更深入全面地了解公司情况、发展战略、经营状况、融资 计划、股权激励、可持续发展等投资者所关心的问题，公司定于 2022 年 6 月 24 日参加由新疆上市公司协会联合深圳市全景网络有限公司组织开展的 2022 年新 疆辖区上市公司投资者网上集体接待日活动。现将有关事项公告如下： 本次集体接待日活动将在深圳市全景网络有限公司提供的网上平台，采取网 络远程的方式举行，投资者可以登录全景网"投资者关系互动平台"网站 （http://ir.p5w.net/）或关注微信公众号：全景财经（微信号：p5w2012），参与 公司本次投资者集体接待日活动，活动时间为 2022 年 6 月 24 日下午（星期五） 15:00 至 17:30。 出席本次集体接待日的人员有：公司董事长郑彩红、轮值总经理荆 ...

Financial Performance - The company's operating revenue for Q1 2022 was CNY 58,796,482.88, representing a year-on-year increase of 24.40%[5] - The net profit attributable to shareholders of the listed company was CNY 1,372,156.64, up 28.00% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 945,756.27, an increase of 122.20% year-on-year[5] - Basic earnings per share were CNY 0.0037, an increase of 27.59% year-on-year[5] - Total operating revenue for Q1 2022 reached ¥58,796,482.88, a 24.3% increase from ¥47,264,446.74 in Q1 2021[17] - Net profit for Q1 2022 was ¥1,378,890.58, representing a 27.3% increase compared to ¥1,083,387.72 in Q1 2021[17] - Total profit for Q1 2022 was ¥2,005,268.37, up from ¥1,763,077.94 in Q1 2021, reflecting a growth of 13.7%[17] Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -12,682,485.50, reflecting a decrease of 6.89% compared to the previous year[5] - Cash flow from operating activities showed a net outflow of ¥12,682,485.50 in Q1 2022, slightly improved from a net outflow of ¥13,620,328.17 in Q1 2021[19] - The company's cash and cash equivalents decreased to RMB 49,289,567.66 from RMB 86,884,849.85, representing a decline of about 43.3%[13] - The company reported cash and cash equivalents of ¥49,289,567.66 at the end of Q1 2022, down from ¥41,785,041.34 at the end of Q1 2021[20] Expenses and Investments - The company's research and development expenses increased by 282.09% compared to the same period last year, indicating a significant investment in R&D[7] - Research and development expenses rose significantly to ¥4,354,071.54 in Q1 2022, compared to ¥1,139,542.38 in Q1 2021, marking an increase of 282.5%[17] - Sales expenses rose by 130.88% year-on-year, primarily due to the expansion of the sales team for business growth[7] - The company experienced a decrease in investment income, reporting a loss of ¥684,735.13 in Q1 2022 compared to a gain of ¥43,802.21 in Q1 2021[17] Assets and Liabilities - The total assets at the end of the reporting period were CNY 980,924,866.39, a slight decrease of 0.14% from the end of the previous year[5] - As of March 31, 2022, the total current assets amounted to RMB 474,176,742.25, a slight increase from RMB 468,093,854.92 at the end of 2021, reflecting a growth of approximately 1.2%[13] - Total liabilities as of March 31, 2022, were RMB 293,293,913.94, a decrease from RMB 296,060,953.02 at the end of 2021, reflecting a reduction of approximately 0.9%[15] - The total equity of the company was RMB 687,630,952.45, slightly up from RMB 686,252,061.87, showing an increase of about 0.2%[15] - Non-current assets totaled RMB 506,748,124.14, down from RMB 514,219,159.97, reflecting a decrease of approximately 1.5%[14] - The company’s total assets were RMB 980,924,866.39, slightly lower than RMB 982,313,014.89 at the end of 2021, indicating a decrease of about 0.1%[14] - The company’s contract liabilities increased to RMB 90,640,179.23 from RMB 85,727,394.43, representing a growth of approximately 5.0%[15] Government Support - The company received government subsidies amounting to CNY 388,403.94, which are closely related to its normal business operations[7]